Microbiotica vs IBM

Side-by-side comparison of AI visibility scores, market position, and capabilities

IBM leads in AI visibility (80 vs 39)
Microbiotica logo

Microbiotica

EmergingBioTech

Microbiome Therapeutics

Microbiotica raised $105M Series C in 2025 for its gut microbiome platform linking bacterial strains to disease, enabling live biotherapeutic products for cancer immunotherapy and IBD.

AI VisibilityBeta
Overall Score
D39
Category Rank
#1 of 2
AI Consensus
75%
Trend
up
Per Platform
ChatGPT
47
Perplexity
43
Gemini
47

About

Microbiotica applies genomics and machine learning to map the gut microbiome's causal role in disease, then develops live biotherapeutic products (LBPs) targeting the specific bacterial strains responsible. The company's Reference Microbiome database — built from thousands of patient samples — is the world's most comprehensive catalog of gut bacteria linked to disease outcomes, providing a systematic foundation for microbiome drug discovery.

Full profile
IBM logo

IBM

LeaderEnterprise Software

General

Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.

AI VisibilityBeta
Overall Score
A80
Category Rank
#56 of 1158
AI Consensus
67%
Trend
up
Per Platform
ChatGPT
74
Perplexity
71
Gemini
84

About

International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).

Full profile

AI Visibility Head-to-Head

39
Overall Score
80
#1
Category Rank
#56
75
AI Consensus
67
up
Trend
up
47
ChatGPT
74
43
Perplexity
71
47
Gemini
84
42
Claude
74
37
Grok
81

Key Details

Category
Microbiome Therapeutics
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Microbiotica
Microbiome Therapeutics
IBM is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.